AtriCure (ATRC) Lifted Its Guidance, Is The Stock Fully Priced?

AtriCure (ATRC) has drawn investor attention after multiple insider share sales. This followed a quarter in which the company reported 13% second quarter revenue growth, a return to net income, and raised full year guidance.

See our latest analysis for AtriCure.

AtriCure’s recent insider sales come against a backdrop of strong share price momentum, with a 57.38% 90 day share price return and 20.74% 30 day share price return, while the 5 year total shareholder return is still down 43.49%.

If this kind of rebound has your attention, it could be a good moment to broaden your watchlist and check out 43 healthcare AI stocks

After AtriCure’s sharp rebound and recent insider selling, the share price now sits between past weakness and upgraded expectations. With analysts and intrinsic estimates also split, where does a reasonable fair value range actually land?

Most Popular Narrative: 11.9% Undervalued

The most followed AtriCure narrative puts fair value at $47.00, above the recent $41.39 close, and builds that gap around specific growth and margin assumptions.

The successful completion of enrollment in the LeAAPS clinical trial, as well as early activation of the BoxX-NoAF study, are set to substantially increase AtriCure's total addressable market if positive outcomes lead to expanded indications for stroke prevention and preventative cardiac surgery in underserved populations, which will support future revenue and earnings growth.

Read the complete narrative.

Want to see what that bigger market actually looks like on a spreadsheet? The story hinges on faster earnings growth, rising margins, and a rich future multiple. Curious which assumptions have to hold for $47.00 to make sense.

Result: Fair Value of $47.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, AtriCure’s story can shift quickly if pulsed field ablation adoption pressures its minimally invasive ablation franchise, or if new AtriClip competitors win share and pricing power.

Find out about the key risks to this AtriCure narrative.

Another View: What AtriCure’s Cash Flows Suggest

While the popular AtriCure narrative lands on a fair value of $47.00 and calls the stock undervalued, the SWS DCF model points in the opposite direction. On that view, the present value of future cash flows sits at just $0.73 per share, which would imply a very stretched price. Which set of assumptions feels more realistic to you?

To see how those cash flow assumptions are built and stress test them against your own expectations, take a closer look at the Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around AtriCure can create both excitement and hesitation, so review the underlying data now and then weigh the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond AtriCure?

If AtriCure has you thinking differently about opportunity and risk, now is the time to widen your search and compare it with other focused stock ideas.

• Spot potential value opportunities early by scanning for companies on the 52 high quality undervalued stocks that also show resilient business fundamentals.
• Strengthen your core holdings by checking out the solid balance sheet and fundamentals stocks screener (48 results) and focus on businesses with healthier financial footing.
• Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before these quieter stories attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com